Importance of Effective Drug Therapy for Prostate Cancer

Prostate Cancer Statistics

With approximately 29,000 men succumbing to prostate cancer each year, the need for effective and safe drug therapies is paramount. Recent clinical trials have shown promising developments in this area.

Understanding Cancer Spread

Cancers generally spread in two primary forms: non-metastatic and metastatic. Non-metastatic cancer is confined and spreads in a linear manner, while metastatic cancer is more aggressive, disseminating throughout the body and exhibiting a high mortality rate. Although prostate cancer is usually non-metastatic, it has the potential to progress to a metastatic form if left untreated.

Current Treatment Approaches

Standard Treatment Methods

The conventional treatment regimen for prostate cancer typically involves androgen deprivation therapy (ADT) combined with chemotherapy. However, certain types of prostate cancer, particularly metastatic castration-resistant prostate cancer (mCRPC), may not respond to hormone therapy.

Rucaparib as a Treatment Option

Researchers are investigating rucaparib, a drug recognized for its efficacy in treating ovarian cancer, as a potential therapy for mCRPC. Rucaparib functions by inhibiting an enzyme that hampers a cell’s ability to repair its DNA, thus preventing cancer cells from healing and proliferating. The drug also blocks the action of polyadenosine diphosphate ribose polymerase (PARP), which has demonstrated effectiveness in prior clinical trials targeting mutations leading to ovarian cancer. Reported side effects have been manageable and primarily include nausea, vomiting, fatigue, and anemia.

TRITON Clinical Trials

Gene Mutations and Cancer Risk

Research has identified the BRCA1 and BRCA2 genes as significant factors in cancer risk. Mutations in these genes can influence the likelihood of developing cancer and the effectiveness of treatment. The TRITON trial primarily assesses whether rucaparib can inhibit the progression of prostate cancer.

Findings from Phase II Trials

During phase II of the TRITON trial, approximately 12% of men with mCRPC exhibited a deletion or alteration in the BRCA gene. This genetic alteration was associated with observable anti-tumor activity in patients receiving rucaparib, confirmed through radiographic evaluations. Consequently, the trial progressed to phase III.

Future Research Directions

Phase III Trial Outlook

The third phase of the TRITON trial is projected to conclude by March 2023. Researchers and healthcare professionals are optimistic about the potential approval of rucaparib as a standard treatment for prostate cancer, especially given that adverse events have been mild to moderate. Future research should focus on identifying markers of PARP activity and developing strategies to inhibit this activity during chemotherapy or radiotherapy.

References

Chandrasekar, T., Yang, J. C., Gao, A. C., & Evans, C. P. (2015). Mechanisms of resistance in castration-resistant prostate cancer (CRPC). Translational Andrology and Urology, 4(3), 365–380. https://doi.org/10.3978/j.issn.2223-4683.2015.05.02

Ryan, C. J., Watkins, S. P., Despain, D., Karlovich, C. A., Simmons, A., Golsorkhi, A. A., & Chowdhury, S. (2017). Trial of rucaparib in prostate indications 3 (TRITON3): An International, Multicenter, randomized, open-label phase 3 study of Rucaparib vs physician’s choice of therapy for patients (PTS) with metastatic castration-resistant prostate cancer (MCRPC) associated with homologous recombination deficiency (HRD). Journal of Clinical Oncology, 35(15_suppl). https://doi.org/10.1200/jco.2017.35.15_suppl.tps5087

Colombo, I., Lheureux, S., & Oza, A. M. (2018). Rucaparib: A novel PARP inhibitor for BRCA advanced ovarian cancer. Drug Design, Development and Therapy, Volume 12, 605–617. https://doi.org/10.2147/dddt.s130809

Abida, W., Patnaik, A., Campbell, D., Shapiro, J., Bryce, A. H., McDermott, R., Sautois, B., Vogelzang, N. J., Bambury, R. M., Voog, E., Zhang, J., Piulats, J. M., Ryan, C. J., Merseburger, A. S., Daugaard, G., Heidenreich, A., Fizazi, K., Higano, C. S., Krieger, L. E., … Chowdhury, S. (2020). Rucaparib in men with metastatic castration-resistant prostate cancer harboring a BRCA1 or BRCA2 gene alteration. Journal of Clinical Oncology, 38(32), 3763–3772. https://doi.org/10.1200/jco.20.01035